Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Real-time Quote. Real-time Tradegate - 05/05 09:59:53 pm
65.11 EUR   +0.98%
05/02 UCB FIRST THREE :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : shareholder meeting today
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
04/29/2016 05/02/2016 05/03/2016 05/04/2016 05/05/2016 Date
65.35(c) 66.34(c) 65.94(c) 64.48(c) 64.97 Last
311 217 306 307 328 059 269 047 216 446 Volume
-3.26% +1.51% -0.60% -2.21% +0.76% Change
More quotes
Financials (€)
Sales 2016 4 048 M
EBIT 2016 721 M
Net income 2016 450 M
Debt 2016 1 026 M
Yield 2016 1,93%
Sales 2017 4 281 M
EBIT 2017 875 M
Net income 2017 548 M
Debt 2017 676 M
Yield 2017 2,02%
P/E ratio 2016 25,35
P/E ratio 2017 20,54
EV / Sales 2016 3,35x
EV / Sales 2017 3,09x
Capitalization 12 542 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
05/05 | 02:00pmPresentation
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
05/02 UCB FIRST THREE MONTHS INTERIM REPOR :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
04/28 UCB : shareholder meeting today
04/25 UCB FIRST THREE MONTHS INTERIM REPOR :
04/21 UCB : Patent Issued for Protein Purification (USPTO 9309280)
04/21 UCB : Patent Issued for Chiral Intermediate, Process for Producing the Same and ..
04/14 UCB : Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab Wit..
More news
Sector news : Pharmaceuticals - NEC
11:25pDJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Report; Nasdaq L..
11:05pDJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Report; Nasdaq L..
11:01p VALEANT PHARMACEUTICALS INTL : Announces Patient Access And Pricing Committee To..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/21 Amgen's romosozumab successful in late-stage study in men with osteoporosis
02/26 UCB backs out of epratuzumab development deal with Immunomedics
02/25 FDA clears Intellipharmaceutics' generic Keppra XR
02/22 Amgen's bone-forming antibody successful in late-stage osteoporosis study
02/19 FDA clears UCB's epilepsy med Briviact


Comments 
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions